晚期胰腺癌治疗进展.ppt

晚期胰腺癌治疗进展;流行病学：常见肿瘤，发病率东西方日趋相似;2012上海国际胰腺癌论坛;胰腺癌早诊困难，预后差;转移性胰腺癌的治疗：突破少、手段有限，吉西他滨到目前为止仍为标准一线化疗;吉西他滨 vs 5-FU 治疗不可切除胰腺癌; 1997-2010.04 III期 RCT;GENCITABINE固定剂量输注速率(FDR);以吉西他滨为基础联合化疗的研究;23RCTs n=5886;;吉西他滨联合新的细胞毒性药物进一步提高疗效？ 吉西他滨之外的新化疗药物、方案的探索？ 靶向药物？ 个体化治疗; Nab-paclitaxel白蛋白结合型紫杉醇;利用独特的纳米技术使疏水性紫杉醇与白蛋白结合，无需使用有毒溶剂 利用了白蛋白天然的独特转运机制(gp60-窖蛋白-SPARC)，使紫杉醇更多分布于肿瘤组织，达到更高的肿瘤细胞内浓度，对肿瘤组织具有主动靶向作用。;白蛋白结合型紫杉醇用于胰腺癌：临床前研究1,2;白蛋白结合型紫杉醇(Abraxane) 联合吉西他滨 对比 单药吉西他滨，显著延长了转移性胰腺癌的生存期。 白蛋白结合型紫杉醇 (Abraxane) 联合吉西他滨成为 转移性胰腺癌一线治疗的标准方案之一。;;;;Von Hoff DD, Ervin T, Arena FP, et al. Randomized Phase III Study of Weekly nab-Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (MPACT) [abstract LBA148]. Oral presentation at: The Gastrointestinal Cancers Symposium 2013; January 24-26; San Francisco, CA.;Von Hoff DD, Ervin T, Arena FP, et al. Randomized Phase III Study of Weekly nab-Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (MPACT) [abstract LBA148]. Oral presentation at: The Gastrointestinal Cancers Symposium 2013; January 24-26; San Francisco, CA.;CA19-9, carbohydrate antigen 19-9; Gem, gemcitabine; KPS, Karnofsky performance status; nab-P, nab-paclitaxel; ULN, upper limit of normal.;Von Hoff DD, Ervin T, Arena FP, et al. Randomized Phase III Study of Weekly nab-Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (MPACT) [abstract LBA148]. Oral presentation at: The Gastrointestinal Cancers Symposium 2013; January 24-26; San Francisco, CA.;;Von Hoff DD, Ervin T, Arena FP, et al. Randomized Phase III Study of Weekly nab-Paclitaxel plus Gemcitabine vs Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas (MPACT) [abstract LBA148]. Oral presentation at: The Gastrointestinal Cancers Symposium 2013; January 24-26; San Francisco, CA.;Von Hoff DD, Ervin T, Arena FP, et al. Randomized Phase III Study of Weekl